Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (251-260 of 430) with videos related to

Pageof 43
Sort By:
Breast Cancer Research : BCR|August 9, 2019
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytesMarcelo Sobral-Leite, Izhar Salomon, Mark Opdam, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2024
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO studyA van Ommen-Nijhof, T G Steenbruggen, T G Wiersma, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Cell Reports|April 6, 2022
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancerSandra Tavares, Nalan Liv, Milena Pasolli, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Human Reproduction (Oxford, England)|July 1, 2022
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocolsEva M E Balkenende, Taghride Dahhan, Catharina C M Beerendonk, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Breast Cancer Research and Treatment|March 4, 2008
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifenMarleen Kok, Sabine C Linn, Ryan K Van Laar, et al.
Pageof 43

Showing results (251-260 of 430) with videos related to

Sort By:
Pageof 43
Breast Cancer Research : BCR|August 9, 2019
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytesMarcelo Sobral-Leite, Izhar Salomon, Mark Opdam, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2024
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO studyA van Ommen-Nijhof, T G Steenbruggen, T G Wiersma, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Cell Reports|April 6, 2022
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancerSandra Tavares, Nalan Liv, Milena Pasolli, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Human Reproduction (Oxford, England)|July 1, 2022
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocolsEva M E Balkenende, Taghride Dahhan, Catharina C M Beerendonk, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Breast Cancer Research and Treatment|March 4, 2008
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifenMarleen Kok, Sabine C Linn, Ryan K Van Laar, et al.
Pageof 43